International Chronic Disease Research Development Workshop May 11–20

The Community Action to Prevent Chronic Disease (CAPCoD) with support from Oxford Health Alliance, will present a series of global health research workshops May 11–20, hosted by the Department of Epidemiology and Public Health (EPH) at Yale School of Medicine, 60 College St.

The International Chronic Disease Research Development workshop is designed to assess promising options for large–scale community intervention research in developing countries and in the United States. Invited participants are principal investigators of 18 potential research projects around the globe and six projects from the U.S. These investigators have prepared their research proposals based on diverse and innovative approaches of population level interventions to change diet, smoking and physical activity through a variety of strategies.

Lars Sorensen, President and Chief Executive Officer of Novo Nordisk A/S will visit Yale to launch the initiative and to discuss future collaboration with Yale.

During the workshop, the international and U.S. research teams will discuss their proposed interventions that plausibly and affordably aim to reduce population burden of chronic diseases in their communities and also exchange their ideas and skills with each other.

“This workshop is opening a new chapter of research and development in chronic diseases all around the world and aims to develop innovative and fundable research projects that will lead to action at the community, national and international level,” said Mahmood Adil, director of Research & Development of CAPCoD Projects and Visiting Scholar from Department of Health for England.

Chronic disease, particularly cardiovascular disease, type 2 diabetes, cancer, and chronic respiratory disease account for over 50 percent of all deaths worldwide. Tobacco use, poor diet and physical inactivity are among the major risk factors contributing to this disease burden.

Four billion people living in low and middle–income countries are now bearing most of the burden of chronic diseases against the myth that these are only health problems of affluent societies. But unlike their colleagues in the U.S., researchers in these countries do not have the capacity or capability to look into the issues and to find local or national solutions to put them ahead of the curve.

To address this issue, the Oxford Alliance, supported by Novo Nordisk A/S. Oxford and Yale Universities initiated CAPCod. These projects are based on applied and community–based research, which is needed to assess the effectiveness of the right interventional approaches in different cultures and settings to deal with chronic diseases in an effective and timely manner.

For further information, please contact Mahmood Adil at 203– 843–7222 or mahmood.adil@yale.edu.